Therapeutic Drug Monitoring of Posaconazole: a Monocentric Study with 54 Adults

Archive ouverte

Lebeaux, David | Lanternier, Fanny | Elie, Caroline | Suarez, Felipe | Buzyn, Agnès | Viard, Jean-Paul | Bougnoux, Marie-Elisabeth | Lecuit, Marc | Vincent, Julien | Lortholary, Olivier

Edité par CCSD ; American Society for Microbiology -

(This work was presented in part at the 19th European Congress of Clinical Microbiology and Infectious Diseases, Helsinki, Finland, 16 to 19 May 2009, and at the 17th Congress of The International Society for Human and Animal Mycology, Tokyo, Japan, 25 to 29 May 2009.). International audience. Posaconazole is a potent broad-spectrum triazole antifungal. Little is known about the prevalence and risk factors for low plasma posaconazole concentrations (PPCs). We retrospectively reviewed all adult patients whose PPCs were measured after at least 5 days of treatment between April 2006 and July 2008 at the Hôpital Necker Enfants Malades. A low PPC was defined as a concentration lower than 500 ng/ml. Fifty-four patients were included: 36 receiving prophylactic (200 mg three times a day) and 18 receiving curative (400 mg twice a day) posaconazole therapy. The prevalence of low PPCs was 44% (16/36) in the prophylaxis group and 22% (4/18) in the curative-treatment group. In the prophylaxis group, low PPCs tended to be more frequent in cases of digestive disease (62.5% versus 30%; P = 0.051) and were significantly more frequent among patients with diarrhea (71.4% versus 27%; P = 0.009) or mucositis (100% versus 33%; P = 0.004). In the curative-treatment group, low PPCs were significantly more frequent in cases of diarrhea (75% versus 7%; P = 0.018). In the prophylaxis group, the only two patients who subsequently developed invasive fungal infections exhibited low PPCs. The only adverse event was hepatotoxicity for 2/54 patients (3.7%), which was not related to high plasma drug concentrations. In conclusion, low PPC is common, significantly more frequent in cases of diarrhea or mucositis, and potentially associated with subsequent invasive fungal infection. Therapeutic drug monitoring of posaconazole is therefore mandatory for immunosuppressed adults, at least for those with gastrointestinal disorders.

Consulter en ligne

Suggestions

Du même auteur

Morganella morganii pericarditis 3 years after allogenic bone marrow transplantation for mantle cell lymphoma

Archive ouverte | Yang, Zhi-Tao | CCSD

International audience. We report herein a case of Morganella morganii-associated acute puru-lent pericarditis that developed 3 years after allogenic bone marrow transplanta-tion. The patient was successfully treate...

Chronic Granulomatous Disease in Patients Reaching Adulthood: A Nationwide Study in France

Archive ouverte | Dunogué, Bertrand | CCSD

International audience. Background : Although prognosis of Chronic Granulomatous Disease (CGD) has greatly improved, few studies have focused on its long-term outcome. We studied the clinical course and sequelae of ...

Antifungal Therapy of Aspergillus Invasive Otitis Externa: Efficacy of Voriconazole and Review

Archive ouverte | Parize, Perrine | CCSD

International audience. ABSTRACT Invasive otitis externa (IOE) due to Aspergillus is a rare, potentially life-threatening, invasive fungal infection affecting immunocompromised patients. The invasive process may lea...

Chargement des enrichissements...